{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-208918","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.615211+00:00","generated_at":"2026-05-14T22:45:36.134943+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"RevMed Q1 net loss $453.8M, daraxonrasib shows OS 13.2 mo in pancreatic cancer","bullets":["Daraxonrasib Phase 3 RASolute 302: median OS 13.2 mo vs 6.7 mo chemo (HR 0.40); NDA submission planned.","Q1 2026 net loss $453.8M vs $213.4M YoY; R&D $344M, G&A $101.3M, including $44.6M incremental SBC.","Cash $1.9B at Mar 31, 2026; April 2026 financings raised $2.225B gross from stock and convertible notes.","FY 2026 GAAP operating expense guidance raised to $1.7-1.8B due to ~$80M increase in non-cash SBC.","Appointed Neil MacGregor JPAC GM, Tetsuo Endo Japan GM, Martin Voelkl Germany GM; EAP for daraxonrasib begun."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-208918","json":"https://secwatch.observer/filing/0001193125-26-208918.json","markdown":"https://secwatch.observer/filing/0001193125-26-208918.md","text":"https://secwatch.observer/filing/0001193125-26-208918.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526208918/0001193125-26-208918-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526208918/rvmd-20260506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:45:36.134943+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2457be261da455f7bd5ae3813c5f9d358a407e3","claim":"Revolution Medicines, Inc. reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2026, and provided an update on corporate progress.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526208918/0001193125-26-208918-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}